002432SZSE

Resolution Announcement of the Fourth Meeting of the Seventh Board of Directors

Andon Health Co., Ltd.·

✨ AI Summary

The Board of Directors of Tianjin Ninehealth Medical Electronic Co., Ltd. held its fourth meeting, approving the 2025 work reports, financial statements, and a profit distribution plan of 16.5 yuan per 10 shares. Key decisions included the cancellation of unexercised stock options and the approval of the 2026 remuneration plan. The meeting also resolved to convene the 2025 Annual General Meeting.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Stock Code: 002432 Stock Abbreviation: Ninehealth Medical Announcement Number: 2026-014 Tianjin Ninehealth Medical Electronic Co., Ltd. Resolution Announcement of the Fourth Meeting of the Seventh Board of Directors

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.

Tianjin Ninehealth Medical Electronic Co., Ltd. (hereinafter referred to as the "Company" or "this Company") issued a notice on April 23, 2026, by way of communication, for the Fourth Meeting of the Seventh Board of Directors. The meeting was held on April 28, 2026, in the Company's conference room with on-site voting. The meeting was presided over by Mr. Liu Yi, Chairman of the Company. Six directors were expected to attend, and six directors actually attended. All senior management personnel of the Company were present at the meeting, in compliance with the "Company Law" and the "Articles of Association." The following proposals were approved by vote:

I. With 6 votes in favor, 0 votes against, and 0 abstentions, the "2025 Work Report of the Board of Directors" was deliberated and approved.

The Company's Board of Directors has strictly followed laws and regulations, normative documents, and the "Articles of Association" to implement the resolutions of the shareholders' meetings, diligently perform its duties, continuously standardize corporate governance, and promote the healthy and stable development of the Company. All directors have diligently performed their duties and played an active role in the scientific decision-making and standardized operation of the Board of Directors. Ms. Bi Xiaofang, Mr. Sun Weijun, and Mr. He Shuguang, independent directors of the Seventh Board of Directors, submitted their "2025 Annual Report of Independent Directors" to the Board of Directors, and will present their reports at the 2025 Annual General Meeting.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.